Nontoxic radioactive Listeria at is a highly effective therapy against metastatic pancreatic cancer
- 22 April 2013
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 110 (21), 8668-8673
- https://doi.org/10.1073/pnas.1211287110
Abstract
No significant improvement in therapy of pancreatic cancer has been reported over the last 25 y, underscoring the urgent need for new alternative therapies. Here, we coupled a radioisotope, 188Rhenium, to an attenuated (at) live Listeria monocytogenes (Listeriaat) using Listeria-binding antibodies, thus creating a unique radioactive Listeriaat (RL). We then demonstrated in a highly metastatic pancreatic mouse tumor model (Panc-02) that RL delivered radioactivity to the metastases and less abundantly to primary tumors in vivo, without harming normal cells. This result was possible because Listeriaat was efficiently cleared by the immune system in normal tissues but not in the heavily immune-suppressed microenvironment of metastases and primary tumor. Multiple treatments with low doses of the RL resulted in a dramatic decrease in the number of metastases (∼90%) compared with control groups in the Panc-02 model. This is the first report of using live attenuated bacteria delivering a highly radioactive payload to the metastases, resulting in killing tumor cells in vivo without harming normal cells. The nontoxic RL treatment is attractive for clinical development as a therapy to prevent pancreatic cancer recurrence and metastases.Keywords
This publication has 25 references indexed in Scilit:
- Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic MelanomaJournal of Skin Cancer, 2013
- Specific antibody-receptor interactions trigger InlAB-independent uptake of listeria monocytogenes into tumor cell linesBMC Microbiology, 2011
- Bacteria in cancer therapy: a novel experimental strategyJournal of Biomedical Science, 2010
- High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of ActionCancer Research, 2009
- The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervixVaccine, 2009
- Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinomaBMC Cancer, 2009
- Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastasesBritish Journal of Cancer, 2008
- Pancreatic CancerAnnual Review Of Pathology-Mechanisms Of Disease, 2008
- The cell biology ofListeria monocytogenesinfectionThe Journal of cell biology, 2002
- Monoclonal antibody to the murine type 3 complement receptor inhibits adhesion of myelomonocytic cells in vitro and inflammatory cell recruitment in vivo.The Journal of Experimental Medicine, 1987